Covid-19 Vaccine Covaxin
- All
- News
- Videos
- Web Stories
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
No External Pressure To Accelerate Development Of Covaxin: Bharat Biotech
Covid-19 vaccine Covaxin maker Bharat Biotech today said there was no external pressure on the firm to speed up its development.
-
Government Rubbishes Reports On Approval For Covaxin Due To Political Pressure
The Union Health Ministry today termed as "misleading" and "fallacious" media reports which claimed that regulatory approval for COVID-19 vaccine Covaxin was rushed due to political pressure.
-
50 Million Doses Of Covaxin Set To Expire Early 2023: Report
Nearly 50 million doses of Bharat Biotech's COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said.
-
Corbevax Approved As Booster Dose For Adults Vaccinated With Covaxin, Covishield
The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
-
Covaxin Booster Enhances Efficacy Against Delta, Omicron Variants: Study
The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.
-
US Health Regulator Lifts Hold On Covaxin's Clinical Trials
The US Food and Drug Administration which has put on hold phase 2/ 3 clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin, in USA, has lifted pause, according to a statement issued by Ocugen Inc, Bharat Biotech's partner for jab in US, Canada
-
Covaxin, Covishield Recipients Had Same Infection Rate In 3rd Wave: Study
Seventy per cent of people who received a booster dose of Covid vaccine did not get infected during the third wave, according to a new study that covered around 6,000 people in India.
-
Covid Booster Shots Off To A Slow Start In Delhi
Administering of precaution dose of COVID-19 vaccines began in Delhi on Sunday amid a steady rise in daily case count in the last few days here, even as the pace was sluggish with a few private vaccination centres starting the exercise.
-
Covaxin Booster Enhances Protection Against Variants Of Concern: ICMR Study
A booster dose of Covaxin administered six months after the two dose primary vaccination has shown elevated immune responses against SARS-CoV-2 variants of concern including Omicron, a study by ICMR and Bharat Biotech has found.
-
Coronavirus Highlights: Covishield, Covaxin Prices Cut To Rs 225
The prices of Covishield and Covaxin vaccines at private hospitals have been slashed by more than half. This comes a day before the Covid vaccine booster shots become available to all Indian adults.
-
Vaccine Not Sent To UN Bodies, Says Bharat Biotech On WHO Action: Sources
With WHO announcing the suspension of Covaxin supply through UN procurement agencies, Bharat Biotech sources said on Monday the pharma company has not supplied the COVID-19 vaccine to any UN agency and no impact of the suspension would be felt.
-
No Impact Of WHO Action On Covaxin, Have Not Supplied To Any UN Agency: Bharat Biotech
With WHO announcing the suspension of Covaxin supply through UN procurement agencies, Bharat Biotech sources said on Monday the pharma company has not supplied the COVID-19 vaccine to any UN agency and no impact of the suspension would be felt.
-
WHO Suspends UN Supply Of Covaxin; No Impact On Efficacy, Says Bharat Biotech
The World Health Organisation said on Saturday it has suspended supply through United Nations agencies of COVID-19 vaccine Covaxin, produced by India's Bharat Biotech, to allow the manufacturer to upgrade facilities.
-
Covaxin Production Slowed Down, This Is What Bharat Biotech Will Focus On
Bharat Biotech on Friday said it is temporarily slowing down production of its COVID-19 vaccine Covaxin across its manufacturing units.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
No External Pressure To Accelerate Development Of Covaxin: Bharat Biotech
Covid-19 vaccine Covaxin maker Bharat Biotech today said there was no external pressure on the firm to speed up its development.
-
Government Rubbishes Reports On Approval For Covaxin Due To Political Pressure
The Union Health Ministry today termed as "misleading" and "fallacious" media reports which claimed that regulatory approval for COVID-19 vaccine Covaxin was rushed due to political pressure.
-
50 Million Doses Of Covaxin Set To Expire Early 2023: Report
Nearly 50 million doses of Bharat Biotech's COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said.
-
Corbevax Approved As Booster Dose For Adults Vaccinated With Covaxin, Covishield
The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
-
Covaxin Booster Enhances Efficacy Against Delta, Omicron Variants: Study
The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.
-
US Health Regulator Lifts Hold On Covaxin's Clinical Trials
The US Food and Drug Administration which has put on hold phase 2/ 3 clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin, in USA, has lifted pause, according to a statement issued by Ocugen Inc, Bharat Biotech's partner for jab in US, Canada
-
Covaxin, Covishield Recipients Had Same Infection Rate In 3rd Wave: Study
Seventy per cent of people who received a booster dose of Covid vaccine did not get infected during the third wave, according to a new study that covered around 6,000 people in India.
-
Covid Booster Shots Off To A Slow Start In Delhi
Administering of precaution dose of COVID-19 vaccines began in Delhi on Sunday amid a steady rise in daily case count in the last few days here, even as the pace was sluggish with a few private vaccination centres starting the exercise.
-
Covaxin Booster Enhances Protection Against Variants Of Concern: ICMR Study
A booster dose of Covaxin administered six months after the two dose primary vaccination has shown elevated immune responses against SARS-CoV-2 variants of concern including Omicron, a study by ICMR and Bharat Biotech has found.
-
Coronavirus Highlights: Covishield, Covaxin Prices Cut To Rs 225
The prices of Covishield and Covaxin vaccines at private hospitals have been slashed by more than half. This comes a day before the Covid vaccine booster shots become available to all Indian adults.
-
Vaccine Not Sent To UN Bodies, Says Bharat Biotech On WHO Action: Sources
With WHO announcing the suspension of Covaxin supply through UN procurement agencies, Bharat Biotech sources said on Monday the pharma company has not supplied the COVID-19 vaccine to any UN agency and no impact of the suspension would be felt.
-
No Impact Of WHO Action On Covaxin, Have Not Supplied To Any UN Agency: Bharat Biotech
With WHO announcing the suspension of Covaxin supply through UN procurement agencies, Bharat Biotech sources said on Monday the pharma company has not supplied the COVID-19 vaccine to any UN agency and no impact of the suspension would be felt.
-
WHO Suspends UN Supply Of Covaxin; No Impact On Efficacy, Says Bharat Biotech
The World Health Organisation said on Saturday it has suspended supply through United Nations agencies of COVID-19 vaccine Covaxin, produced by India's Bharat Biotech, to allow the manufacturer to upgrade facilities.
-
Covaxin Production Slowed Down, This Is What Bharat Biotech Will Focus On
Bharat Biotech on Friday said it is temporarily slowing down production of its COVID-19 vaccine Covaxin across its manufacturing units.
